DelveInsight’s ‘Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017–2030
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).
The DelveInsight Idiopathic Pulmonary Fibrosis (IPF) market report gives the thorough understanding of the Idiopathic Pulmonary Fibrosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Idiopathic Pulmonary Fibrosis in the US, Europe and Japan.
The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of IPF, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.
According to DelveInsight, the total number of prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in 7 MM was found to be 229,170, in the year 2017.
This segment of the Idiopathic Pulmonary Fibrosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, there are two approved drugs in the market; Esbriet (Pirfenidone) and Ofev (Nintedanib) aims at slowing down the disease progression through acting like anti-fibrotic mediators. Nintedanib is a potent intracellular inhibitor of the receptor tyrosine kinases PDGFR, FGFR, vascular endothelial growth factor receptor (VEGFR) and non-receptor tyrosine kinases of the Src family; Pirfenidone, on the other, is responsible for reducing markers of oxidative stress, reducing the proliferation of lung fibroblasts and their differentiation into myofibroblasts by attenuating key TGF-β-induced signalling pathways (i.e., Smad3, p38, and Akt), reducing the expression of TGF-β-induced heat-shock protein 47 (HSP47), which is involved in processing/secretion of procollagen, and reducing expression of α smooth muscle actin (α-SMA) and collagen type 1.
The Idiopathic Pulmonary Fibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 1,510.4 Million in 2017, and is expected to increase during the course of the study period (2017–2030).
Among the 7MM, the United States accounts for the largest market size of IPF, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
What is Idiopathic Pulmonary Fibrosis?
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma, associated with significant morbidity and poor prognosis.
What was the Idiopathic Pulmonary Fibrosis market size in the 7 major markets (7MM)?
Idiopathic Pulmonary Fibrosis Market Size was 1,510 Million in the 7MM in 2017
Which geography accounted for the largest Idiopathic Pulmonary Fibrosis market size?
The US accounted for the largest Idiopathic Pulmonary Fibrosis market size among the 7MM
What are the Idiopathic Pulmonary Fibrosis market drivers?
The grant of special regulatory designations, several therapies in the pipeline from various companies, an increase in the prevalence of fibrotic diseases are the Idiopathic Pulmonary Fibrosis market drivers
What are the Idiopathic Pulmonary Fibrosis market barriers?
The prognosis of patients with Idiopathic Pulmonary Fibrosis remains poor, lack of accurate diagnostic procedures and, specific validating biomarkers, Idiopathic Pulmonary Fibrosis is associated with high mortality rates are the Idiopathic Pulmonary Fibrosis market barriers
How many companies are developing drugs for Idiopathic Pulmonary Fibrosis?
MediciNova, FibroGen, Kadmon Corporation, Promedior, Inc, Galapagos NV are developing drugs for Idiopathic Pulmonary Fibrosis
1. Key Insights
2. Idiopathic Pulmonary Fibrosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2017
2.2. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2028
3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)
3.1. Introduction
3.2. Statistics about Idiopathic Pulmonary Fibrosis
3.3. Staging of Idiopathic Pulmonary Fibrosis
3.4. Risk Factors and Disease Causes
3.5. Symptoms
3.6. Pathogenesis
3.7. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Prevalent Population of Idiopathic Pulmonary Fibrosis
5. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis
5.1. United States
5.1.1. Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States
5.1.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.1.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.1.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2. EU5
5.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5
5.2.2. Germany
5.2.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
5.2.2.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.2.2.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.2.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.3. France
5.2.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
5.2.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.2.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.4. Italy
5.2.4.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
5.2.4.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.2.4.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.4.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.5. United Kingdom
5.2.5.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
5.2.5.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.2.5.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.5.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.6. Spain
5.2.6.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
5.2.6.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.2.6.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.2.6.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
5.3. Japan
5.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
5.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
5.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
5.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
6. Current Treatment Practices
6.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
6.2. Patient Journey
7. Unmet Needs
8. Organizations contributing toward IPF
9. KOL’s Views: Idiopathic Pulmonary Fibrosis
10. Case Reports
10.1. Idiopathic Pulmonary Fibrosis: As case Discussion in the US
10.2. Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report of Europe
10.3. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis – A Japanese Case Report
11. Marketed Products
11.1.Esbriet (Pirfenidone): InterMune Inc.
11.1.1. Product Description
11.1.2. Regulatory Milestones
11.1.3. Advantages & Disadvantages
11.1.4. Safety and Efficacy of Esbriet
11.1.5. Side effects of Esbriet
11.1.6. Product Profile
11.2.Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Advantages and Disadvantages
11.2.4. Safety and Efficacy of Ofev
11.2.5. Side effects of Ofev
11.2.6. Product Profile
12. Emerging Therapies
12.1. Key Cross Competition
12.2.Tipelukast: MediciNova
12.2.1. Drug Description
12.2.2. Clinical Development
12.2.3. Clinical Trials Information
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.3.Pamrevlumab: FibroGen
12.3.1. Drug Description
12.3.2. Regulatory Milestones
12.3.3. Other Development Activities
12.3.4. Clinical Development
12.3.5. Clinical Trials Information
12.3.6. Safety and Efficacy
12.3.7. Product Profile
12.4.KD025: Kadmon Corporation, LLCs
12.4.1. Drug Description
12.4.2. Other Development Activities
12.4.3. Clinical Development
12.4.4. Clinical Trials Information
12.4.5. Safety and Efficacy
12.4.6. Product Profile
12.5.PRM 151: Promedior, Inc.
12.5.1. Drug Description
12.5.2. Regulatory Milestones
12.5.3. Other Development Activities
12.5.4. Clinical Development
12.5.5. Clinical Trials Information
12.5.6. Safety and Efficacy
12.5.7. Product Profile
12.6.GLPG1690: Galapagos NV
12.6.1. Drug Description
12.6.2. Regulatory Milestones
12.6.3. Other Development Activities
12.6.4. Clinical Development
12.6.5. Clinical Trials Information
12.6.6. Safety and Efficacy
12.6.7. Product Profile
13. Other Promising Candidates
13.1.CC-90001: Celgene Corporation
13.1.1. Drug Description
13.1.2. Clinical Development
13.1.3. Clinical Trials Information
13.1.4. Safety and Efficacy
13.1.5. Product Profile
13.2.LT-1001: Beijing Tide Pharmaceutical
13.2.1. Drug Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.4. Clinical Trials Information
13.2.5. Safety and Efficacy
13.2.6. Product Profile
13.3.LT-1002: Chong Kun Dang Pharmaceutical
13.3.1. Drug Description
13.3.2. Other Development Activities
13.3.3. Clinical Development
13.3.4. Clinical Trials Information
13.3.5. Product Profile
13.4.BG00011: Biogen Inc.
13.4.1. Drug Description
13.4.2. Regulatory Milestones
13.4.3. Other Development Activities
13.4.4. Clinical Development
13.4.5. Clinical Trials Information
13.4.6. Safety and Efficacy
13.4.7. Product Profile
13.5.PBI4050: ProMetic Life Sciences
13.5.1. Drug Description
13.5.2. Regulatory Milestones
13.5.3. Other Development Activities
13.5.4. Clinical Development
13.5.5. Clinical Trials Information
13.5.6. Safety and Efficacy
13.5.7. Product Profile
13.6.TD139: Galecto Biotech
13.6.1. Drug Description
13.6.2. Other Development Activities
13.6.3. Clinical Development
13.6.4. Clinical Trials Information
13.6.5. Safety and Efficacy
13.6.6. Product Profile
13.7.VAY736: Novartis
13.7.1. Drug Description
13.7.2. Other Development Activities
13.7.3. Clinical Development
13.7.4. Clinical Trials Information
13.7.5. Product Profile
13.8.TAS-115: Taiho Pharmaceutical
13.8.1. Drug Description
13.8.2. Clinical Development
13.8.3. Clinical Trials Information
13.8.4. Product Profile
13.9.ND-L02-s0201: Nitto Denko Corporation
13.9.1. Drug Description
13.9.2. Other Development Activities
13.9.3. Clinical Development
13.9.4. Clinical Trials Information
13.9.5. Safety and Efficacy
13.9.6. Product Profile
13.10. Nalbuphine ER: Trevi Therapeutics
13.10.1. Drug Description
13.10.2. Clinical Development
13.10.3. Clinical Trials Information
13.10.4. Product Profile
13.11. RVT-1601: Respivant Sciences
13.11.1. Drug Description
13.11.2. Clinical Development
13.11.3. Clinical Trials Information
13.11.4. Safety and Efficacy
13.11.5. Product Profile
13.12. Gefapixant: Merck & Co.
13.12.1. Drug Description
13.12.2. Other Development Activities
13.12.3. Clinical Development
13.12.4. Clinical Trials Information
13.12.5. Safety and Efficacy
13.12.6. Product Profile
14. Idiopathic Pulmonary Fibrosis: Market Analysis
14.1. Key Findings
14.2. Total Market Size of Idiopathic Pulmonary Fibrosis in 7MM
14.3. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in 7MM
15. Market Size of Idiopathic Pulmonary Fibrosis by Country
15.1.United States Market Analysis
15.1.1. Market Size of Idiopathic Pulmonary Fibrosis in the US
15.1.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US
15.2.EU5 Market Outlook
15.2.1. Germany
15.2.1.1. Market Size of Idiopathic Pulmonary Fibrosis in Germany
15.2.1.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany
15.2.2. France
15.2.2.1. Market Size of Idiopathic Pulmonary Fibrosis in France
15.2.2.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France
15.2.3. Italy
15.2.3.1. Market Size of Idiopathic Pulmonary Fibrosis in Italy
15.2.3.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy
15.2.4. United Kingdom
15.2.4.1. Market Size of Idiopathic Pulmonary Fibrosis in the UK
15.2.4.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the UK
15.2.5. Spain
15.2.5.1. Market Size of Idiopathic Pulmonary Fibrosis in Spain
15.2.5.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain
15.3.Japan: Market Analysis
15.3.1. Market Size of Idiopathic Pulmonary Fibrosis in Japan
15.3.2. Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan
16. Market Drivers of Idiopathic Pulmonary Fibrosis
17. Market Barriers of Idiopathic Pulmonary Fibrosis
18. Appendix
18.1. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
List Of Tables:
Table 1: Expected 1-year probability of death in patients with idiopathic pulmonary fibrosis
Table 2: The GAP (Gender, Age, and Physiology) score
Table 3: The GAP index and staging system
Table 4: High resolution computed tomography criteria for up pattern
Table 5: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 6: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 7: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Table 8: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 9: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 10: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 11: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 12: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Table 13: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 14: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 15: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 16: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Table 17: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 18: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 19: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 20: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Table 21: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 22: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 23: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 24: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Table 25: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 26: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 27: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 28: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Table 29: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 30: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 31: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 32: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Table 33: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 34: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Table 35: Dosage of Pirfenidone
Table 36: Dosage of Nintedanib
Table 37: Interpretation of Strong and Conditional Recommendations for Stakeholders (Patients, Clinicians, and Health Care Policy-Makers):
Table 38: Comparison of recommendations in 2015 and 2011 IPF Guidelines
Table 39: Organizations contributing toward IPF
Table 40: Key Cross Analysis of Emerging Therapies
List Of Figures:
Figure 1: Risk factors associated with IPF
Figure 2: IPF associated clubbing of the fingertips
Figure 3: Stages of the pathogenesis of IPF
Figure 4: A schematic representing the current model for the pathogenesis of IPF
Figure 5: Possible mechanisms of fibrogenesis in IPF
Figure 6: Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower lobe reticular opacities (red circles)
Figure 7: Sub pleural honeycombing in IPF diagnosed patients
Figure 8: ATS/ERS criteria for the diagnosis of idiopathic pulmonary fibrosis in the absence of surgical lung biopsy (2000).
Figure 9: Combination of high-resolution computed tomography and surgical lung biopsy for the diagnosis of IPF (requires multidisciplinary discussion)
Figure 10: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF). Patients with suspected IPF
Figure 11: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 12: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 13: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Figure 14: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 15: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 16: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 17: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 18: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Figure 19: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 20: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 21: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 22: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Figure 23: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 24: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 25: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 26: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Figure 27: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 28: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 29: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 30: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Figure 31: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 32: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 33: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 34: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Figure 35: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 36: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 37: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 38: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017–2030
Figure 39: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
Figure 40: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017–2030
• FibroGen
• Kadmon Corporation LLC
• Promedior Inc.
• Galapagos NV
• MediciNova
• Ashai Kasei Pharma Corporation
• Celgene Corporation
• Beijing Tide Pharmaceutical
• Chong Kun Dang Pharmaceutical
• Biogen Inc.
• ProMetic Life sciences
• Galecto Biotech
• Novartis
• Taiho Pharmaceutical
• Nitto Denko Corporation
• Trevi Therapeutics
• Respivant Sciences
• Merck & Co
